2017年8月17日 · Strong evidence supports that these 11 emerging IHC markers or their combinations may be useful in predicting prognosis and aiding personalized therapy decision-making for ESCC patients.

2024年10月18日 · Here we show that ESCC can be categorized into differentiated, metabolic, immunogenic and stemness subtypes based on bulk and single-cell RNA-seq, each exhibiting specific molecular and...

Esophageal cancer is classified by histology as esophageal squamous carcinoma (ESCC) and esophageal adenocarcinoma. ESCC is the most common histological subtype and represents up to 90% of cases in the highest risk areas of the “esophageal cancer belt,” which stretches from Northern Iran through Central Asia to China (1, 3 - 5).

2021年12月17日 · Here, we analyze the microenvironment of esophageal squamous cell carcinoma (ESCC) using single-cell transcriptome sequencing in 62,161 cells from blood, adjacent nonmalignant and matched tumor...

食管鳞状上皮癌前病变（Esophageal squamous precancerous lesions, ESPL）是ESCC的前体病变，表现出从正常上皮（NE）到低级别（LGIN）和高级别（HGIN） 上皮内瘤变 的进展，最终发展为浸润性癌。 一份长达13.5年的随访数据表明，较高级别的上皮内瘤变与ESCC发生的风险明显相关。 目前， 尚不明确哪些阶段的ESPL最终会发展成ESCC，因此需要找到与ESPL进展为ESCC相关的风险指标，以进行精准预防。

2024年1月2日 · Esophageal squamous cell carcinoma (ESCC) is one of the most lethal malignancies in the world with poor prognosis. Despite the promising applications of...

2024年5月9日 · This study successfully elucidates the functional role of CD276 in ESCC. Our comprehensive analysis uncovers the significant role of CD276 in modulating immune surveillance mechanisms in ESCC, thereby suggesting that targeting CD276 might serve as a potential therapeutic approach for ESCC treatment.

This study evaluated the expression of proliferating cell nuclear antigen (PCNA), tumor suppressor protein p53, epidermal growth factor receptor (EGFR), and vascular endothelial growth factor (VEGF) as biomarkers for ESCC. Methods: This study included 60 clinical cases (30 ESCC and 30 non-ESCC cases that were confirmed pathologically).

2017年8月17日 · Strong evidence supports that these 11 emerging IHC markers or their combinations may be useful in predicting prognosis and aiding personalized therapy decision-making for ESCC patients.

In summary, we profiled the immune status in ESCC and established predictive and prognostic factors for ESCC, which could reflect immune disorders within tumor microenvironments and independently distinguish patients with a high risk of reduced survival, providing novel predictive and therapeutic targets for ESCC patients in the future.